Most doctors are not categorically against bisphosphonates, but a significant and growing number have become reluctant to prescribe them, creating what osteoporosis researchers have called a treatment “crisis.” The gap between the number of patients who could benefit from these drugs and the number who actually receive them has widened over the past decade, driven largely by physician and patient fears about rare but alarming side effects. The irony is real: bisphosphonates remain among the most effective fracture-prevention drugs available, yet the medical community’s own wariness has left many high-risk patients untreated.
What Bisphosphonates Actually Do
Bisphosphonates are bone-avid compounds, meaning they bind tightly to bone tissue. They work by suppressing osteoclasts, the cells responsible for breaking down old bone during the normal remodeling cycle. By slowing that breakdown, they help preserve bone density and micro-architecture, both of which determine how resistant your skeleton is to fractures.1PubMed Central. Bisphosphonates and bone quality A large meta-analysis found that bisphosphonate use reduced the risk of osteoporotic fracture overall by about 38%, with even steeper reductions for vertebral fractures specifically.2PubMed Central. The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis Those numbers are why, for decades, bisphosphonates have been considered first-line therapy for osteoporosis. The controversy is not about whether they work. It is about whether their risks justify caution in how broadly they are used and for how long.
The Side Effects That Spooked the Medical Community
Three side effects, in particular, have shaped the debate. Each is genuinely documented, but each has also been amplified by media coverage and word-of-mouth in ways that can distort the actual level of risk.
Atypical Femoral Fractures
This is the complication that gets the most attention. Unlike ordinary hip fractures caused by a fall, atypical femoral fractures occur with little or no trauma, typically along the shaft of the thighbone, and they are linked to prolonged bisphosphonate use. A large study in the New England Journal of Medicine found that the risk of atypical fracture climbed steeply with duration of use: compared with patients who had taken bisphosphonates for less than three months, those on therapy for eight years or more had a hazard ratio above 43.3PubMed Central. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates A Scandinavian study similarly found the odds of atypical fracture roughly doubled with each additional year of use, reaching very high odds ratios after four or more years.4PubMed Central. Risk of atypical femoral fracture during and after bisphosphonate use
Those relative risk numbers look terrifying in isolation. But the absolute risk is small. The Scandinavian study estimated about 11 additional atypical fractures per 10,000 patient-years of bisphosphonate use.5PubMed Central. Risk of atypical femoral fracture during and after bisphosphonate use For most patients at high risk of ordinary fragility fractures, the number of fractures prevented by the drug far exceeds the number of atypical fractures caused by it. The reassuring finding from the NEJM study is that stopping bisphosphonates leads to a rapid decrease in atypical fracture risk, so the problem is largely manageable through duration limits and drug holidays.6PubMed Central. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates
Osteonecrosis of the Jaw
Osteonecrosis of the jaw (ONJ) is a condition where bone tissue in the jaw dies, leading to exposed bone, infection, and painful, slow-healing wounds. It became a major source of alarm after reports surfaced in cancer patients receiving high-dose intravenous bisphosphonates. A review of early case reports found that roughly 94% of ONJ cases occurred in patients on intravenous bisphosphonates, with only about 6% in patients taking the oral forms typically prescribed for osteoporosis.7PubMed. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates That distinction matters enormously, because the doses and drugs used for cancer treatment are far higher than those used for osteoporosis, but the public and even some clinicians have not always drawn that line clearly.
When ONJ does occur in oral bisphosphonate users, it tends to be less severe. A study comparing patients with ONJ from oral versus intravenous bisphosphonates found that the oral group had fewer affected sites on average and needed fewer surgeries, while outcomes after surgery were also better in the oral group.8PubMed Central. Characteristics of patients with osteonecrosis of the jaw with oral versus intravenous bisphosphonate treatment That said, the very existence of ONJ as a possibility has had outsized effects on clinical behavior, particularly in dentistry.
Gastrointestinal Problems
Oral bisphosphonates can irritate the lining of the esophagus and stomach. An endoscopy study of patients on oral bisphosphonates found esophageal mucosal injury in about 10% of patients and gastroduodenal ulcers in about 4%.9Internal Medicine. Symptoms and Upper Gastrointestinal Mucosal Injury Associated with Bisphosphonate Therapy These issues are the most common reason patients struggle with oral bisphosphonates in daily practice, and physicians surveyed about noncompliance ranked gastrointestinal intolerance as the top reason their patients stop taking the drugs.10PubMed Central. Physicians’ perspectives on the treatment of osteoporosis patients with bisphosphonates While not life-threatening, GI side effects are the most tangible day-to-day problem patients face, and they erode adherence in a way that can make the medication functionally useless.
The Treatment Gap and Why It Matters
The backlash against bisphosphonates has had measurable consequences. Researchers have documented a widening gap between the number of patients who need osteoporosis treatment and those who actually get it. A 2017 commentary in the Journal of Bone and Mineral Research described this as a crisis, noting that many patients who need pharmacological therapy are either not being prescribed medications or are not taking them, and that a major driver is physician and patient concerns about side effects like atypical femoral fractures.11PubMed. Addressing the Crisis in the Treatment of Osteoporosis: A Path Forward
This is a genuine clinical problem. Osteoporotic fractures, particularly hip fractures, carry high rates of disability and death in older adults. The drugs that prevent them are well-studied and widely available, many now as inexpensive generics. Yet prescribing rates have dropped. In a survey of primary care physicians, 61% cited potential adverse effects as a factor limiting their treatment decisions, alongside cost concerns.12Mayo Clinic Proceedings. Barriers to Osteoporosis Identification and Treatment Among Primary Care Physicians and Orthopedic Surgeons General practitioners in particular have reported uncertainty about treatment choice and difficulty navigating the risk-benefit conversation with patients.13PubMed Central. Clinicians’ views of prescribing oral and intravenous bisphosphonates for osteoporosis: a qualitative study
How Media Coverage Shaped Prescribing
The role of alarming news stories in driving down bisphosphonate use should not be underestimated. Research into media effects has found that alarming information in the media over the past two decades regarding the effectiveness and safety of long-term osteoporosis treatment is associated with a reduction in the use of osteoporosis medications.14PubMed. Adverse effects of media reports on the treatment of osteoporosis The pattern is familiar from other medications: a rare side effect gets dramatic coverage, patients bring the story to their doctor’s office, and the physician, already uncertain about duration and risk, decides it is easier not to prescribe than to have the conversation.
In New Zealand, media publicity about osteonecrosis of the jaw created enough alarm that some dentists began refusing to perform dental work on patients taking bisphosphonates, and some patients stopped their osteoporosis treatment entirely out of fear.15Prescriber Update. Osteonecrosis Of The Jaw And Bisphosphonates – Putting The Risk In Perspective This ripple effect, where concern in one specialty changes behavior in another, is one of the less visible ways bisphosphonate skepticism spreads through the healthcare system.
Drug Holidays as a Compromise
Rather than simply continuing or stopping bisphosphonates indefinitely, most guidelines now recommend planned breaks from treatment, commonly called drug holidays. The logic is built into the pharmacology: because bisphosphonates accumulate in bone and continue to suppress bone resorption for months or years after you stop taking them, you can pause treatment and still retain some protection against fractures.16PubMed Central. Bisphosphonate drug holiday: who, when and how long
The general recommendation is a drug holiday of two to three years for most patients after long-term bisphosphonate therapy, based primarily on extension data from pivotal trials of alendronate and zoledronate.17PubMed Central. Duration of Bisphosphonate Drug Holidays in Osteoporosis Patients: A Narrative Review of the Evidence and Considerations for Decision-Making A meta-analysis found that discontinuation may be reasonable for women who do not have low hip bone density after three to five years of initial treatment, while women who still have low hip bone density may be better served by continuing.18PubMed Central. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk In practice, more than 80% of physicians surveyed said they incorporate drug holidays into their prescribing patterns at least some of the time.19PubMed Central. Physicians’ perspectives on the treatment of osteoporosis patients with bisphosphonates
Drug holidays solve the duration problem elegantly on paper. In practice, the challenge is knowing when to restart. Bone density scans change slowly, sometimes too slowly to catch someone losing protection during a holiday. This is where newer monitoring tools come in.
Monitoring During and After Treatment
Bone turnover markers, which are blood tests measuring how actively your body is breaking down and building bone, change much more quickly than bone density measurements. A consensus statement from Asia-Pacific experts endorsed the use of two specific markers, CTX and P1NP, as short-term monitoring tools to help clinicians assess treatment response and adjust regimens earlier than waiting for bone density scans.20PubMed. Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region Researchers have also argued that these markers could help identify patients who are not good candidates for a drug holiday, because their bone turnover bounces back too quickly after stopping treatment, putting them at higher risk of fracture sooner.21PubMed Central. Can bone turnover markers help to define the suitability and duration of bisphosphonate drug holidays?
For primary care doctors unsure about who actually needs treatment in the first place, the FRAX algorithm offers a way to quantify a patient’s 10-year fracture probability using clinical risk factors and bone density data. Current guidelines suggest treating patients whose 10-year hip fracture risk is 3% or higher, or whose major osteoporotic fracture risk is 20% or higher.22PubMed. Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men Tools like FRAX can help doctors who feel uncertain about bisphosphonate prescribing focus on the patients who stand to benefit the most, rather than applying a blanket yes-or-no approach.
When Doctors Choose Alternatives Instead
Some of the shift away from bisphosphonates reflects not rejection but substitution. For patients at very high fracture risk, newer anabolic agents, drugs that stimulate new bone formation rather than just slowing its breakdown, have shown superior results. A meta-analysis of randomized controlled trials found that anabolic agents like teriparatide and romosozumab significantly reduced the incidence of new vertebral fractures compared with bisphosphonates such as alendronate and risedronate.23PubMed Central. Comparison of the Clinical Efficacy of Anabolic Agents and Bisphosphonates in the Patients With Osteoporotic Vertebral Fracture Pivotal trial data suggest that these agents reduce both vertebral and non-vertebral fractures faster and to a greater degree than potent antiresorptive treatments alone.24Endocrine Practice. Anabolic Therapy and Optimal Treatment Sequences for Patients With Osteoporosis at High Risk for Fracture
The emerging consensus is that for high-risk patients, the ideal sequence is to start with an anabolic agent and then transition to a bisphosphonate or other antiresorptive to maintain the gains.25PubMed Central. Anabolic therapy for osteoporosis: update on efficacy and safety Bisphosphonates, in other words, still have a role even in the most aggressive treatment strategies. They are not being replaced so much as repositioned within a broader playbook.
Denosumab, another antiresorptive but not a bisphosphonate, has also gained popularity, particularly for patients who cannot tolerate oral bisphosphonates. It is given as an injection every six months, avoiding the GI issues entirely. But denosumab has its own problem: when you stop taking it, its bone-protective effects reverse quickly, and patients can experience rebound fractures. Bisphosphonates are actually the recommended follow-up treatment after denosumab discontinuation, precisely because they linger in bone and prevent that rebound.26PubMed Central. The Role of Bisphosphonates Prior to Denosumab Treatment on Rebound Fractures Doctors who avoid bisphosphonates entirely may inadvertently leave patients vulnerable when transitioning off denosumab.
The Overdiagnosis Question
Some physicians’ skepticism about bisphosphonates runs deeper than side-effect concerns. It extends to the very definition of who counts as a patient needing treatment. Before the late 1980s, osteoporosis was diagnosed only after someone broke a bone. A 1994 redefinition, based on bone mineral density thresholds, expanded the pool of potential patients dramatically. The introduction of fracture risk calculators pushed it further. A BMJ analysis argued that current fracture risk predictors have at least doubled the number of candidates for drug treatment, and that under U.S. guidelines, about 75% of white women over 65 have become candidates for pharmacotherapy.27BMJ. Overdiagnosis of bone fragility in the quest to prevent hip fracture
This is a legitimate concern that exists independently of any drug’s side effects. If the diagnostic net is cast too broadly, many people labeled as patients and prescribed bisphosphonates are at low enough actual fracture risk that the drugs’ modest absolute risk of harm may not be worth it. Doctors who push back against routine bisphosphonate prescribing may, in some cases, be reacting less to the drug itself and more to a system that has steadily lowered the bar for who qualifies as sick. The distinction matters, because the fix for overly broad diagnostic criteria is better targeting of treatment, not avoidance of effective medication in patients who genuinely need it.
Generic Formulations and Tolerability
One factor that rarely makes headlines but quietly affects the prescribing landscape is the quality of generic bisphosphonates. Since alendronate went off patent, generic versions have dominated the market. But evidence suggests that many generic formulations are more poorly tolerated than the original branded preparations, leading to significantly worse adherence and, by extension, reduced effectiveness.28PubMed Central. A reappraisal of generic bisphosphonates in osteoporosis A patient who switches to a generic, experiences more stomach irritation, and then quits the drug entirely may never know that the problem was the formulation rather than the active ingredient. Their doctor, seeing another patient who “couldn’t tolerate bisphosphonates,” adds one more tally to the mental ledger of reasons to avoid the drug class.
This creates a self-reinforcing cycle. Poor tolerability of generics drives noncompliance, noncompliance gets attributed to the drug itself, and the growing stack of “bad experiences” feeds the broader narrative that bisphosphonates are too problematic to prescribe freely. It is worth asking, in any given case of reported intolerance, whether a different formulation or route of administration (such as an annual intravenous infusion of zoledronate) might solve the problem without abandoning the drug class.
The Dentist’s Office Problem
Dentists occupy an unusual position in the bisphosphonate debate. Because osteonecrosis of the jaw is the side effect most directly relevant to dental care, dentists are often the first clinicians patients hear express concern about bisphosphonates. Some dental practitioners have gone further and declined to perform procedures on bisphosphonate users, even those on low-dose oral therapy for osteoporosis where the absolute risk of ONJ is very small.29Prescriber Update. Osteonecrosis Of The Jaw And Bisphosphonates – Putting The Risk In Perspective This refusal can cascade: a patient told by their dentist that their osteoporosis medication is dangerous may stop it without consulting the prescribing physician, or the physician may preemptively stop the drug before a dental procedure and never restart it.
The legal dimension adds another layer. The rare but serious nature of ONJ has generated lawsuits, and the awareness of litigation risk can influence prescribing behavior on both the dental and medical sides.30PubMed Central. Bisphosphonate-related osteonecrosis of the jaw: historical, ethical, and legal issues associated with prescribing A doctor who prescribes a bisphosphonate to a patient who later develops ONJ faces one kind of liability risk; a doctor who does not prescribe one to a patient who later suffers a hip fracture faces another. The current climate, shaped by media coverage and patient awareness, tilts the perceived risk toward the side-effect lawsuit rather than the undertreated-fracture lawsuit. That asymmetry may explain some of the prescribing reluctance better than any pure clinical calculation.
Who Actually Benefits Most From Bisphosphonates
The fracture-prevention benefits of bisphosphonates are clearest in patients with the highest fracture risk: those who have already broken a bone, those with very low bone density at the hip, and those with multiple risk factors stacking up on tools like FRAX. For these patients, the absolute risk reduction from bisphosphonates is large enough that the drug’s small absolute risk of atypical fracture or jaw problems is easily justified. The meta-analytic data showing a roughly 45% reduction in vertebral fractures and about 27% reduction in non-vertebral fractures represent meaningful protection in this group.31PubMed Central. The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis
The picture gets murkier for patients at lower risk, people with mildly reduced bone density and no prior fractures, who may be prescribed bisphosphonates primarily because they crossed a numerical threshold on a scan. For them, the absolute number of fractures prevented over five years is smaller, and the risk-benefit ratio narrows. Some physicians who are described as being “against bisphosphonates” are really expressing frustration with treating a lab value rather than treating a patient whose skeleton is genuinely in trouble. When a doctor hesitates to prescribe, it is worth asking whether the hesitation reflects a blanket fear of the drug or a reasonable judgment that this particular patient may not need it.